Optimer Pharmaceuticals Announces Data Presented at ECCMID Illustrate Risk Factors for Negative Outcomes in C. Difficile Patients

Optimer Pharmaceuticals, Inc. OPTR today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID™ (fidaxomicin) for the treatment of Clostridium difficile infection. The data resulted from analysis of specific risk factors associated with negative outcomes in patients with CDI, including immunosuppression and alcohol abuse.